Abstract:Dear Editor, Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide variety of presenting features. Many studies have suggested cytokines are involved in the pathogenesis of SLE.1-4 Interleukin (IL)-35, a heterodimeric cytokine composed of the subunits EBI3 and p35, was recently identified as a new member of the IL-12 cytokine family.5 The role of IL-35 remains controversial in inflammatory diseases. Some studies have shown its anti-inflammatory properties given its effect on Treg, regulator B cells and associated cytokines in inflammatory bowel disease, collagen-induced arthritis or other autoimmune diseases.6-8 In contrast, IL-35 enhanced the inflammatory response in Lyme arthritis9 and IL-35 gene therapy exacerbates experimental rheumatoid arthritis in mice.10 The expression and significance of IL-35 in patients with SLE is still obscure. Several studies have shown that the level of IL-35 was decreased and the percentage of CD4+ EBI3+ T cells were also significantly decreased in patients with active SLE.11, 12 Another study showed that plasma IL-35 and soluble gp130 levels were significantly higher in patients with severe SLE.13 We conducted this study to investigate the IL-35 level in patients with SLE and their potential association with clinical manifestations and disease activity. We enrolled 145 patients with SLE (133 females and 12 males, mean age 35.6 ± 13.9 years) and 69 age- and sex-matched healthy volunteers without diseases. The protocol for the study was approved by the Ethics Committee of Peking University People's Hospital (FWA00001384). Clinical and laboratory features of SLE patients were recorded. Serum levels of IL-35 were measured by enzyme-linked immunosorbent assay according to the manufacturer's protocol (USCN Life Science, Wuhan, China). The levels of serum IL-35 were significantly higher in patients with SLE than in healthy controls (125.7 ± 110.5 vs. 19.1 ± 45.4, t = 10.050, P = 0.0000) (Fig. 1). The levels of IL-35 were significantly higher in SLE patients with SLE Disease Activity Index (SLEDAI) scores ≥ 8 than patients with SLEDAI score < 8 (85.29 vs. 54.57, Z = −4.314, P = 0.000). The levels of serum IL-35 were correlated with anti-double-stranded DNA antibodies (r = 0.214, P = 0.010) and SLEDAI scores(r = 0.326, P = 0.000) (Fig. 2). The levels of serum IL-35 decreased significantly in accordance with disease activity after treatment in a subgroup of 19 patients with SLE (Fig. 3). Serum levels of IL-35 were associated with photosensitivity (115.5 ± 96.2 vs. 194.1 ± 170.5, t = −2.945, P = 0.004), arthritis (109.8 ± 104.5 vs. 161.4 ± 118.5, t = −2.636, P = 0.009) and fever (109.3 ± 103.9 vs. 161.3 ± 119.1, t = −2.672, P = 0.008) (Table 1). We could see that IL-35 levels were lower in SLE patients with antiphospholipid syndrome (APS) than those without APS, but there was no statistical difference between these two groups. In conclusion, we demonstrate circulating IL-35 is significantly higher than healthy controls and associate with disease activity in SLE. IL-35 might be involved in the pathogenesis of SLE. This work was supported by the National Nature Science Foundation of China (grant no. NSFC.81202297). The authors have no conflicts of interest to declare.

Inverse Association Between Antiviral Immunity and Lupus Disease Activity

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus

Analysis of Microrna-199A-3p Expression in CD4 + T Cells of Systemic Lupus Erythematosus

Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon

Association Of Increased Interferon-Inducible Gene Expression With Disease Activity And Lupus Nephritis In Patients With Systemic Lupus Erythematosus

Investigation of the caspase-dependent mitochondrial apoptotic pathway in mononuclear cells of patients with systemic lupus erythematosus

Vitamin D and systemic lupus erythematosus: Causality and association with disease activity and therapeutics

A retrospective cohort study of Epstein-Barr virus infection status and systemic lupus erythematosus

Expression level of Interferon regulatory factor 5 in systemic lupus erythematosus

Dynamic analysis of the relationship between systemic lupus erythematosus disease activity and psychosocial support

Correlation between levels of dendritic cell subsets in systemic lupus erythematosus patients and SLEDAI

Study of the Relationship Between the ANA Anti-dsDNA and the Disease Activity of First Diagnostical SLE In-patients

[Correlations Between Viral Serology and Different Clinical Characteristics in Patients with Lupus Nephropathy].

Elevated Serum Interleukin-35 Is Associated With Disease Activity In Patients With Systemic Lupus Erythematosus

Study of T-lymphocyte Activation and Correlation with Disease Activity in Patients with Systemic Lupus Erythematosus

Lymphocyte Apoptosis and Macrophage Function: Correlation with Disease Activity in Systemic Lupus Erythematosus

Expressions of interferon-inducible genes in patients with systemic lupus erythematosus and their assoc-iation with disease activity

A Study on MDA5 Signaling in Splenic B Cells from an Imiquimod-Induced Lupus Mouse Model with Proteomics

Longitudinal antinuclear antibody titers in systemic lupus erythematosus and other rheumatic diseases